Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022

SELL
$2.59 - $3.92 $4,535 - $6,863
-1,751 Closed
0 $0
Q1 2021

Apr 30, 2021

SELL
$7.52 - $15.55 $8,129 - $16,809
-1,081 Reduced 38.17%
1,751 $16,000
Q4 2020

Jan 27, 2021

SELL
$5.0 - $8.85 $2,225 - $3,938
-445 Reduced 13.58%
2,832 $19,000
Q2 2020

Jul 10, 2020

SELL
$4.84 - $8.02 $27,336 - $45,296
-5,648 Reduced 63.28%
3,277 $19,000
Q1 2020

Apr 17, 2020

SELL
$4.52 - $8.55 $24,407 - $46,170
-5,400 Reduced 37.7%
8,925 $50,000
Q4 2019

Jan 22, 2020

SELL
$6.14 - $9.3 $154,789 - $234,453
-25,210 Reduced 63.77%
14,325 $109,000
Q3 2019

Oct 15, 2019

SELL
$9.05 - $16.02 $52,200 - $92,403
-5,768 Reduced 12.73%
39,535 $357,000
Q2 2019

Jul 12, 2019

BUY
$13.58 - $18.61 $249,586 - $342,033
18,379 Added 68.26%
45,303 $0
Q1 2019

Apr 24, 2019

BUY
$11.31 - $23.7 $155,218 - $325,258
13,724 Added 103.97%
26,924 $0
Q4 2018

Jan 31, 2019

BUY
$6.8 - $12.88 $14,960 - $28,336
2,200 Added 20.0%
13,200 $137,000
Q3 2018

Oct 24, 2018

BUY
$5.65 - $13.75 $62,150 - $151,250
11,000 New
11,000 $0

Others Institutions Holding CRON

About Cronos Group Inc.


  • Ticker CRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 377,896,000
  • Market Cap $718M
  • Description
  • Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of...
More about CRON
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.